LeMaitre Vascular (LMAT)
(Delayed Data from NSDQ)
$86.05 USD
+1.02 (1.20%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $86.08 +0.03 (0.03%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Brokerage Reports
LeMaitre Vascular, Inc. [LMAT]
Reports for Purchase
Showing records 1 - 20 ( 191 total )
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Resuming Coverage - Initiating Coverage
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
We are updating our Healthcare coverage to reflect a recent analyst departure and to drop
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Optimized Entry and Exit Levels for LMAT 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Medical Technology: Suspending Coverage of 21 Companies
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
1Q23 Recap - Hitting on All Cylinders (Volume/Price)
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S